NTRK gene fusions involving either NTRK1, NTRK2, or NTRK3 are oncogenic drivers of multiple adult and pediatric tumor types. NTRK genes can become abnormally fused to other genes resulting in growth signals that can lead to cancer in many organs. These fusions can be detected using a number of methods, including tumor DNA and RNA sequencing and plasma cell-free DNA profiling.
Why join the collaboration:
Receive one 10 µm Seraseq® FFPE NTRK Fusion RNA Reference section, with 15 clinically relevant NTRK fusion genes to use as positive reference standard in molecular assay testing (PCR or NGS) of NTRK gene fusions in adult and pediatric cancer patients
To benefit from this opportunity, please ensure that lab assay details in “Assay Management” section reflects the following information for Q2 2021:
· NSCLC disease volumes and corresponding NTRK & RET biomarker volumes and testing methods/assays
· Thyroid Cancer disease volumes and corresponding NTRK & RET biomarker volumes and testing methods/assays
· Breast Cancer disease volumes and corresponding NTRK & BRCA biomarker volumes and testing methods/assays
The information above will help Diaceutics understand how testing is performed in your lab and will enable us to design strategies to support testing and patient treatment.
If your lab does not perform molecular testing for some of the requested biomarkers, please send us a message via “Ask a question”.